Answers are grounded in this paper and cite their sources.
Research on tumor metabolic reprogramming has long centered on glucose, lipids and free amino acids. By contrast, di/tripeptides, which lie at the interface between protein breakdown products and functional metabolic signals, have only recently begun to be recognized as a distinct molecular tier in cancer biology. Compared with longer peptides, di/tripeptides display greater metabolic mobility and a clearer dependence on dedicated transport systems. Here we systematically review the sources, transport, metabolic use, biological functions and clinical translational potential of di/tripeptides in cancer. Current evidence indicates that di/tripeptides arise from endogenous protein degradation, dietary digestion and microbial metabolism. Under nutrient limitation, tumor cells can recover amino acids through carnosine dipeptidase 2 (CNDP2)-mediated extracellular cleavage of dipeptides or uptake of intact di/tripeptides followed by intracellular hydrolysis. Beyond their role as nutrient substrates, selected di/tripeptides directly influence tumor cell proliferation, invasion, metastasis and drug resistance, and shape the tumor microenvironment by modulating acid base balance, redox homeostasis, angiogenesis and immune cell function. At the clinical translational level, di/tripeptides have emerged as candidate metabolomic and peptidomic biomarkers, transporter targeted imaging probes, functionally modified therapeutic agents and engineered delivery modules. Di/tripeptides should be viewed as molecular nodes that connect tumor nutrient adaptation, signaling control, microenvironmental remodeling and clinical translation, with significance extending beyond their role as transient intermediates in protein metabolism.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: